JO3061B1 - صور بلورية من 3- ( 2، 6- ثانى كلورو – 3، 5- ثانى ميثوكسى فينيل) – 1- { 6- [ 4- (4- ايثيل – بيبرازين – 1- يل) – فينيل أمينو ] – بيريميدين – 4- يل } – 1- ميثيل – يوريا وأملاح منها - Google Patents
صور بلورية من 3- ( 2، 6- ثانى كلورو – 3، 5- ثانى ميثوكسى فينيل) – 1- { 6- [ 4- (4- ايثيل – بيبرازين – 1- يل) – فينيل أمينو ] – بيريميدين – 4- يل } – 1- ميثيل – يوريا وأملاح منهاInfo
- Publication number
- JO3061B1 JO3061B1 JOP/2010/0433A JOP20100433A JO3061B1 JO 3061 B1 JO3061 B1 JO 3061B1 JO P20100433 A JOP20100433 A JO P20100433A JO 3061 B1 JO3061 B1 JO 3061B1
- Authority
- JO
- Jordan
- Prior art keywords
- phenyl
- images
- crystalline
- dichloro
- pyrimidine
- Prior art date
Links
- XGEGHDBEHXKFPX-UHFFFAOYSA-N N-methylthiourea Natural products CNC(N)=O XGEGHDBEHXKFPX-UHFFFAOYSA-N 0.000 title abstract 2
- -1 methoxy phenyl Chemical group 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 238000000034 method Methods 0.000 abstract 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 abstract 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 abstract 1
- 150000004683 dihydrates Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000000877 morphologic effect Effects 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 238000003672 processing method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26715509P | 2009-12-07 | 2009-12-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JO3061B1 true JO3061B1 (ar) | 2017-03-15 |
Family
ID=43983750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2010/0433A JO3061B1 (ar) | 2009-12-07 | 2010-12-05 | صور بلورية من 3- ( 2، 6- ثانى كلورو – 3، 5- ثانى ميثوكسى فينيل) – 1- { 6- [ 4- (4- ايثيل – بيبرازين – 1- يل) – فينيل أمينو ] – بيريميدين – 4- يل } – 1- ميثيل – يوريا وأملاح منها |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US9067896B2 (https=) |
| EP (1) | EP2509963B1 (https=) |
| JP (2) | JP5714024B2 (https=) |
| KR (1) | KR101787784B1 (https=) |
| CN (5) | CN111100077A (https=) |
| AR (2) | AR079257A1 (https=) |
| AU (1) | AU2010328391B2 (https=) |
| BR (1) | BR112012013784B1 (https=) |
| CA (1) | CA2781431C (https=) |
| CL (1) | CL2012001480A1 (https=) |
| DK (1) | DK2509963T3 (https=) |
| EC (1) | ECSP12012026A (https=) |
| ES (1) | ES2562462T3 (https=) |
| GT (1) | GT201200181A (https=) |
| HR (1) | HRP20160126T1 (https=) |
| HU (1) | HUE026983T2 (https=) |
| IL (1) | IL220012B (https=) |
| JO (1) | JO3061B1 (https=) |
| MA (1) | MA33849B1 (https=) |
| MX (1) | MX2012006562A (https=) |
| MY (1) | MY158333A (https=) |
| NZ (3) | NZ700778A (https=) |
| PE (1) | PE20121499A1 (https=) |
| PH (2) | PH12012501146A1 (https=) |
| PL (1) | PL2509963T3 (https=) |
| RU (1) | RU2572848C2 (https=) |
| SG (1) | SG10201408063SA (https=) |
| SI (1) | SI2509963T1 (https=) |
| TN (1) | TN2012000263A1 (https=) |
| TW (1) | TWI526440B (https=) |
| WO (1) | WO2011071821A1 (https=) |
| ZA (1) | ZA201203612B (https=) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0512324D0 (en) * | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| AR079257A1 (es) * | 2009-12-07 | 2012-01-04 | Novartis Ag | Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| US20150072019A1 (en) * | 2012-03-30 | 2015-03-12 | Novartis Ag | Fgfr inhibitor for use in the treatment of hypophosphatemic disorders |
| ES2704744T3 (es) | 2012-06-13 | 2019-03-19 | Incyte Holdings Corp | Compuestos tricíclicos sustituidos como inhibidores de FGFR |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| AR094812A1 (es) | 2013-02-20 | 2015-08-26 | Eisai R&D Man Co Ltd | Derivado de piridina monocíclico como inhibidor del fgfr |
| TWI647220B (zh) | 2013-03-15 | 2019-01-11 | 美商西建卡爾有限責任公司 | 雜芳基化合物及其用途 |
| MY181020A (en) | 2013-03-15 | 2020-12-16 | Sanofi Sa | Heteroaryl compounds and uses thereof |
| WO2014155268A2 (en) | 2013-03-25 | 2014-10-02 | Novartis Ag | Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity |
| EA035095B1 (ru) | 2013-04-19 | 2020-04-27 | Инсайт Холдингс Корпорейшн | Бициклические гетероциклы в качестве ингибиторов fgfr |
| EP3019491A4 (en) | 2013-07-09 | 2016-12-21 | Dana Farber Cancer Inst Inc | KINASEHEMMER FOR THE TREATMENT OF DISEASES |
| MX378288B (es) * | 2013-10-18 | 2025-03-10 | Eisai R&D Man Co Ltd | Inhibidores de pirimidina del fgfr4. |
| NZ719865A (en) * | 2013-12-13 | 2022-07-29 | Novartis Ag | A pharmaceutical dosage form produced from the wet granulation of 3-(2,6-dichloro-3,5- dimethoxy-phenyl)-1-{ 6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl} -1-methylurea |
| MA38393B1 (fr) | 2014-03-13 | 2018-11-30 | Sanofi Sa | Composés hétéroaryle et utilisations associées |
| KR102344105B1 (ko) | 2014-08-18 | 2021-12-29 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 모노시클릭 피리딘 유도체의 염 및 이의 결정 |
| US20170304313A1 (en) | 2014-10-06 | 2017-10-26 | Novartis Ag | Therapeutic Combination For The Treatment Of Cancer |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| MX373169B (es) | 2015-02-20 | 2020-04-24 | Incyte Holdings Corp | Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr). |
| EP3273959A1 (en) * | 2015-03-25 | 2018-01-31 | Novartis Ag | Pharmaceutical combinations |
| ES2887148T3 (es) | 2015-03-25 | 2021-12-21 | Nat Cancer Ct | Agente terapéutico contra el cáncer de vías biliares |
| SG10201810057UA (en) | 2015-04-14 | 2018-12-28 | Eisai R&D Man Co Ltd | Crystalline fgfr4 inhibitor compound and uses thereof |
| CN104803925B (zh) * | 2015-04-16 | 2018-01-12 | 温州医科大学 | 一类以fgfr为靶点的2，4，5‑三取代嘧啶类化合物及其制备方法和用途 |
| WO2016189472A1 (en) | 2015-05-28 | 2016-12-01 | Novartis Ag | Fgfr inhibitor for use in the treatment of the phosphaturic mesenchymal tumor |
| US12414945B2 (en) | 2015-12-17 | 2025-09-16 | Eisai R&D Management Co., Ltd. | Therapeutic agent for breast cancer |
| EP3454898B1 (en) | 2016-05-10 | 2021-11-10 | Eisai R&D Management Co., Ltd. | Drug combinations for reducing cell viability and/or cell proliferation |
| JP6667014B2 (ja) * | 2016-05-20 | 2020-03-18 | 浙江海正薬業股▲ふん▼有限公司Ｚｈｅｊｉａｎｇ Ｈｉｓｕｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ ＣＯ．，ＬＴＤ． | ピリミジン誘導体、その調製方法および医療での使用 |
| CN109803684B (zh) * | 2016-08-23 | 2022-08-23 | 卫材 R&D 管理有限公司 | 用于治疗肝细胞癌的组合疗法 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| CN107176954B (zh) | 2017-06-02 | 2019-01-11 | 无锡双良生物科技有限公司 | 一种egfr抑制剂的药用盐及其晶型、制备方法和应用 |
| US11440903B2 (en) | 2017-11-01 | 2022-09-13 | Guangdong Zhongsheng Pharmaceutical Co., Ltd | Salt form and crystal form of compound as FGFR4 inhibitor and preparation method thereof |
| SG11202007591RA (en) | 2018-03-28 | 2020-09-29 | Eisai R&D Man Co Ltd | Therapeutic agent for hepatocellular carcinoma |
| MA52493A (fr) | 2018-05-04 | 2021-03-10 | Incyte Corp | Sels d'un inhibiteur de fgfr |
| CR20200590A (es) | 2018-05-04 | 2021-04-26 | Incyte Corp | Formas sólidas de un inhibidor de fgfr y procesos para prepararlas |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| TWI891666B (zh) | 2019-10-14 | 2025-08-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之雙環雜環 |
| CN119462616A (zh) * | 2019-10-14 | 2025-02-18 | 和记黄埔医药（上海）有限公司 | 化合物的盐及其晶型 |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| BR112022010664A2 (pt) | 2019-12-04 | 2022-08-16 | Incyte Corp | Derivados de um inibidor de fgfr |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CA3202267A1 (en) * | 2020-12-18 | 2022-06-23 | Riccardo Panicucci | Methods of treating achondroplasia |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法 |
| EP4352059A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2022261159A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| EP4358847A4 (en) | 2021-06-23 | 2025-05-21 | Kimtron, Inc. | System and method for ultra-close irradiation of rotating biomass |
| JP7802200B2 (ja) * | 2022-03-18 | 2026-01-19 | 上▲海▼▲潤▼石医▲薬▼科技有限公司 | 置換のアミノ６員窒素複素環式化合物の塩及びその結晶形、製造方法と応用 |
| CN115785001B (zh) * | 2022-11-23 | 2023-09-15 | 斯坦德药典标准物质研发(湖北)有限公司 | 一种英菲格拉替尼的制备方法 |
| JP2026507903A (ja) | 2023-03-06 | 2026-03-06 | キューイーディー セラピューティクス，インコーポレイテッド | 骨格形成異常の治療方法 |
| AU2024345848A1 (en) * | 2023-09-18 | 2026-04-09 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Pharmaceutical composition containing heteroaryl oxynaphthalene compound, preparation method therefor, and use thereof |
| WO2025090870A1 (en) | 2023-10-27 | 2025-05-01 | Qed Therapeutics, Inc. | Infigratinib and metabolites thereof for use in methods of treating skeletal disorders |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0512324D0 (en) * | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| CN101242843A (zh) * | 2005-06-10 | 2008-08-13 | 詹森药业有限公司 | 作为激酶调节剂的氨基嘧啶类化合物 |
| KR101486490B1 (ko) * | 2005-11-08 | 2015-01-27 | 제이더블유중외제약 주식회사 | α-헬릭스 유사체 및 암 줄기세포의 치료에 관한 방법 |
| BRPI0620408B8 (pt) * | 2005-12-21 | 2021-05-25 | Novartis Ag | derivados de pirimidinil aril uréia sendo inibidores de fgf, seus usos, e preparação farmacêutica |
| CA2720888A1 (en) * | 2008-04-29 | 2009-11-05 | Novartis Ag | Methods of monitoring the modulation of the kinase activity of fibroblast growth factor receptor and uses of said methods |
| AR079257A1 (es) * | 2009-12-07 | 2012-01-04 | Novartis Ag | Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas |
-
2010
- 2010-12-03 AR ARP100104472A patent/AR079257A1/es not_active Application Discontinuation
- 2010-12-05 JO JOP/2010/0433A patent/JO3061B1/ar active
- 2010-12-06 ES ES10788479.3T patent/ES2562462T3/es active Active
- 2010-12-06 JP JP2012543183A patent/JP5714024B2/ja active Active
- 2010-12-06 EP EP10788479.3A patent/EP2509963B1/en active Active
- 2010-12-06 MX MX2012006562A patent/MX2012006562A/es active IP Right Grant
- 2010-12-06 BR BR112012013784-0A patent/BR112012013784B1/pt active IP Right Grant
- 2010-12-06 CN CN201911272657.2A patent/CN111100077A/zh active Pending
- 2010-12-06 CN CN201911278014.9A patent/CN111269186A/zh active Pending
- 2010-12-06 CN CN2010800550783A patent/CN102639510A/zh active Pending
- 2010-12-06 TW TW099142438A patent/TWI526440B/zh active
- 2010-12-06 NZ NZ700778A patent/NZ700778A/en unknown
- 2010-12-06 CN CN201911273119.5A patent/CN111100078A/zh active Pending
- 2010-12-06 SG SG10201408063SA patent/SG10201408063SA/en unknown
- 2010-12-06 WO PCT/US2010/059108 patent/WO2011071821A1/en not_active Ceased
- 2010-12-06 RU RU2012128351/04A patent/RU2572848C2/ru active
- 2010-12-06 PH PH1/2012/501146A patent/PH12012501146A1/en unknown
- 2010-12-06 MY MYPI2012002222A patent/MY158333A/en unknown
- 2010-12-06 KR KR1020127017618A patent/KR101787784B1/ko active Active
- 2010-12-06 DK DK10788479.3T patent/DK2509963T3/en active
- 2010-12-06 NZ NZ624315A patent/NZ624315A/en unknown
- 2010-12-06 US US13/514,308 patent/US9067896B2/en active Active
- 2010-12-06 SI SI201031119A patent/SI2509963T1/sl unknown
- 2010-12-06 PH PH12014502593A patent/PH12014502593A1/en unknown
- 2010-12-06 PE PE2012000772A patent/PE20121499A1/es active IP Right Grant
- 2010-12-06 CN CN201510484635.8A patent/CN105061332A/zh active Pending
- 2010-12-06 NZ NZ600070A patent/NZ600070A/en unknown
- 2010-12-06 AU AU2010328391A patent/AU2010328391B2/en active Active
- 2010-12-06 HR HRP20160126T patent/HRP20160126T1/hr unknown
- 2010-12-06 PL PL10788479T patent/PL2509963T3/pl unknown
- 2010-12-06 CA CA2781431A patent/CA2781431C/en active Active
- 2010-12-06 HU HUE10788479A patent/HUE026983T2/en unknown
-
2012
- 2012-05-17 ZA ZA2012/03612A patent/ZA201203612B/en unknown
- 2012-05-24 IL IL220012A patent/IL220012B/en active IP Right Grant
- 2012-05-25 TN TNP2012000263A patent/TN2012000263A1/en unknown
- 2012-06-06 CL CL2012001480A patent/CL2012001480A1/es unknown
- 2012-06-07 GT GT201200181A patent/GT201200181A/es unknown
- 2012-06-26 MA MA35005A patent/MA33849B1/fr unknown
- 2012-07-05 EC ECSP12012026 patent/ECSP12012026A/es unknown
-
2015
- 2015-01-20 JP JP2015008550A patent/JP6019142B2/ja active Active
-
2019
- 2019-01-07 AR ARP190100029A patent/AR114946A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JO3061B1 (ar) | صور بلورية من 3- ( 2، 6- ثانى كلورو – 3، 5- ثانى ميثوكسى فينيل) – 1- { 6- [ 4- (4- ايثيل – بيبرازين – 1- يل) – فينيل أمينو ] – بيريميدين – 4- يل } – 1- ميثيل – يوريا وأملاح منها | |
| CY1124874T1 (el) | Διεργασια για την παρασκευη [(5-(3-χλωροφαινυλ)-3-υδροξυπυριδινο-2-καρβονυλ)-αμινο]οξικου οξεος απο 5-((3-χλωροφαινυλ)-3-χλωρο-πυριδιν-2-υλ)-νιτριλιο, και διεργασια για την παρασκευη παραγωγων 5-((αλογονοφαινυλ)-3-αλογονο-πυριδιν-2-υλ)-νιτριλιου | |
| IL189375A0 (en) | 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero)aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors | |
| WO2009083940A3 (en) | Processes for the preparation of 2,5-dihydroxybenzenesulfonic acid salts | |
| GB0418900D0 (en) | Novel salt forms | |
| TN2011000504A1 (en) | Liquid formulations of salts of 1-[2-(2,4- dimethylphenylsulfanyl) phenyl] piperazine | |
| IL222348B (en) | Process for the preparation of 4- {4-[({[4 -chloro-3 -(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorophenoxy}-n-methylpyridine-2-carboxamide, its salts and monohydrate | |
| MX2010008583A (es) | Novedosos formas cristalinas de acido 4-[4-(2-adamantilcarbamoil)- 5-ter-butil-pirazol-1-il]benzoico. | |
| MX2014004529A (es) | Solucion para administracion oral. | |
| MX2010001938A (es) | Metodos para preparar compuestos basados en 4-fenil-6-(2,2,2-trifl uoro-1-feniletoxi)pirimidina. | |
| PH12012500992A1 (en) | Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use | |
| WO2011104723A3 (en) | Acid addition salts of ivabradine and preparation method thereof | |
| IL225557A (en) | Preparation Method (3s, 3s) 4,4'-Disulfandylbis (3-Aminobutane 1 - Sulfonic Acid) | |
| IN2015DN00568A (https=) | ||
| GEP20084494B (en) | New heterocyclic carboxylic acid amide derivatives | |
| SMT201400064B (it) | Procedimento per la produzione di acido 2-[(3,5-difluoro-3'-metossi-1,1'-bifenil-4-il) amino] nicotinico | |
| WO2011042890A3 (fr) | Utilisation de composés phénoliques pour la déglycation des protéines | |
| TN2012000361A1 (en) | Process for the preparation of 2-(cyclohexylmethyl)-n-{2- [(2s)-1-methylpyrrolidin-2-yl]ethyl}-1, 2, 3, 4- tetrahydroisoquinoline-7-sulfonamide | |
| WO2012015255A3 (en) | Novel montelukast 4-halobenzylamine salt and method for preparing montelukast sodium salt by using the same | |
| EA201001270A1 (ru) | Новый способ получения сульфонилпирролов в качестве ингибиторов гистондезацетилаз (hdac) | |
| WO2014167509A3 (en) | Loxoprofen polymorphs and process for preparation of the same | |
| EA201270223A1 (ru) | ЭНАНТИО- И СТЕРЕОСПЕЦИФИЧЕСКИЕ СИНТЕЗЫ β-АМИНО-α-ГИДРОКСИАМИДОВ | |
| CY1117185T1 (el) | Κρυσταλλικες μορφες της 3-(2,6-διχλωρο-3,5-διμεθοξυ-φαινυλ)-1-{6-[4-(4-αιθυλ-πιπεραζιν-1-υλ)-φαινυλαμινο]-πυριμιδιν-4-υλ}-1-μεθυλ-ουριας και αλατα αυτων | |
| GR20110100398A (el) | Μεθοδος για την παρασκευη αλατος του 3-(ν-μεθυλ-ν-πεντυλ) αμινο-1-υδροξυπροπανιο-1,1-διφωσφονικου οξεος, αλατος ή παραγωγων αυτου | |
| UA44953U (ru) | Применение калиевых солей 2-б-аланино- и 2-глицино-3-хлор-1,4-нафтохинона как актопротекторных средств |